Inventiva S.A. ADR (IVA) Stock Price, Quote & News

Company Profile

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 33 3 80 44 75 00

Website: inventivapharma.com

Address:

50 rue de Dijon, Daix, France

S_Franconi Mar. 16 at 12:09 PM

$IVA 592 watchers. March 16, 2026 @Trainguy1 @Catlover37.

0 · Reply

BioRich Mar. 12 at 1:27 PM

$ALT @2MargaritaLunch Chop, this kind of post is EXACTLY why the $ALT board continues to remain disconnected on $ALT's reality. Let me help: 1) Statistically, drugs that received BTD have a 65-72% probability for approval compared to 50-60% for Phase 3 drugs, overall. 46% BTDs are in Oncology. 2) Current 4 drugs in the MASH sector with BTD (Including $IVA, which leads in Fibrosis Improvement, and $SGMT, which shows excellent results with $MDGL). 3) No MASH drug that has applied for BTD has been denied. This is expected given the early stages of sector development and multiple (potential) MOAs. So thanks for sharing your hopium of success based on receiving BTD, but I think right-sizing those expecations for $ALT is more warranted than most, especially given they are significantly lagging behind excellent performing companies that are significantly further along than $ALT Cheers!

1 · Reply

rational1 Mar. 12 at 12:44 PM

$SGMT $MDGL $GSK $IVA $ALGS

0 · Reply

Quantumup Mar. 12 at 12:08 PM

Citizens reiterated $SGMT Market Outperform; $35 and said, We continue to like SGMT's position in MASH, with the denifanstat/resmetirom combo targeting F4 MASH, which is the highest unmet need. $MDGL $IVA NVO LLY ALGS RHHBY ALGS VKTX $BHC $DRMA BFRI Here's what else Citizens had to say: https://x.com/Quantumup1/status/2032065360715784492?s=20

0 · Reply

Quantumup Mar. 11 at 8:27 PM

Oppenheimer reiterated $SGMT Outperform/$25, and said: SGMT reported 4Q25 results with $10.8M OpEx and $113.1M cash providing expected runway into 3Q27. $MDGL $IVA $NVO $ALGS VKTX RHHBY DRMA BFRI Oppenheimer added—We see key recent progress and several upcoming catalysts, including: 1) Ph1 PK study of the denifanstat plus resmetirom combination now supports a Ph2 trial in F4 MASH patients expected to initiate in 2H26; 2) partner Ascletis recently reported positive 52-week Ph3 results for denifanstat in moderate/severe acne demonstrating efficacy with favorable safety/tolerability supporting NDA filing acceptance by the Chinese NMPA, and we expect approval and launch in China ~early 2027; 3) Next-gen. FASN inhibitor TVB-3567 for acne Ph1 study data remains on track for 2026 followed by a Ph2 study pending regulatory alignment. We believe the differentiated MOA of FASN inhibition remains underappreciated while upcoming data readouts could drive upside.

0 · Reply

YouVSYou Mar. 10 at 12:47 AM

Daily Charts in focus $IVA $CADL $IMRX $SLS

2 · Reply

BioRich Mar. 7 at 8:29 PM

$ALT @Turribull How far you've fallen. As your cognitive dissonance appears to be driving your recent word salads and desperation, let me help a few questions you thought the answer was "no" to: 1) Did fundamentals change? Yes, but I'd be eager to hear what fundamentals you think didn't change for better understanding of your thought process. 2) Did data change? No, but that doesn't actually benefit $ALT. The harsh reality is that Pemvi has significantly under-performed. Scrapped Obesity, MASH Failed Fibrosis Improvement, HDL, LDL, Total Cholesterol, Triglycerides and showed weight regain in the 1.2mg and lowering LFC reduction durability as trials went on. So no, data didn't change, understanding and acknowledging it has. 3) Did cash runway change? Yes. 4) Did FDA endorsements change? FDA has never endorsed $ALT. Do they have BTD? Sure, but that doesn't seem to matter. No MASH candidate has been denied BTD, and 4 have it (including Fibrosis leader ($IVA).

0 · Reply

BioRich Mar. 4 at 6:16 PM

$ALT More reasons why REAL INVESTORS don't believe the hYpe. This outlines why there's significant concern about $ALT's DURABILITY with Pemvi. Liver Fat Content (LFC) Reduction with trial and time: MASLD P1b (12W): 1.2mg: 46.6% LFC Reduction 1.8mg: 68.5% 2.4mg: 57.1% MASLD P1b (24W): 1.2mg: 56.3% LFC Reduction 1.8mg: 75.2% 2.4mg: 76.4% MASH P2b (24W): 1.2mg: 52% LFC Reduction 1.8mg: 57.7% MASH P2b (48W): 1.2mg: 45.2% LFC Reduction 1.8mg: 54.7% So yes, $ALT data is concerning and the durability for Pemvi is lackluster, at best. This is just one of many reasons $ALT trails $IVA (which I believe gets a deal based on Fibrosis results), $SGMT (deal with $MDGL), $MDGL and $NVO. If you organically look at the data, you'll realize why WS uses $ALT ticker as a cat toy and why $ALT (the company) has a bleak, dilution-driven future. Follow/Subscribe for more thoughts and perspective. Would love to hear yours too. That's how we learn. Cheers!

1 · Reply

BioRich Feb. 27 at 4:01 AM

$IVA Been seeing a lot of articles lately touting $IVA heavily. I tend to agree as their Fibrosis Improvement to date is the best I've seen. I still believe that $SNY makes a deal with them. Time will tell. Here's a good read: https://finance.yahoo.com/news/nash-mash-treatment-market-surpass-113000913.html

0 · Reply

BioRich Feb. 23 at 5:42 PM

$ALT Oh Billy Irish, you continue to fall short of expectations and continue to share misleading information. What the article said (in order): 1) $IVA - "Inventiva’s upcoming Phase III readout for pan-PPAR agonist lanifibranor is “the biggest event in the MASH space” this year, according to Nash." 2) $VKTX - "Viking Therapeutics has long attracted significant interest from Big Pharma. With pipeline assets that target both obesity and MASH, analysts have marked the biotech as one likely to draw suitors. 3) $ALT - "Altimmune’s pemvidutide stands apart from others in the MASH pipeline due to its ability to preserve lean muscle mass, as well as ensuring MASH resolution and weight loss, a company spokesperson told BioSpace in an email." 4) $SGMT - Like pemvidutide, Sagimet Biosciences’ denifanstat, an oral, once-daily fatty acid synthase (FASN) inhibitor that blocks the production of new fat in the liver, holds FDA Breakthrough Therapy Designation in MASH. Do Better Desperate $ALT Pumper Billy.

0 · Reply

Market Cap	874.25M
Revenue (ttm)	15.93M
Net Income (ttm)	-199.34M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,251.35%
Debt to Equity Ratio	-6.42

Volume	70,500
Avg Vol	476,624
Day's Range	N/A - N/A
Shares Out	145.95M
Stochastic %K	15%
Beta	0.71
Analysts	Strong Sell
Price Target	$15.48